Investigator
Fellow Physician · University of California, Irvine Medical Center, Obstetrics and Gynecology
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer
Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic.
Fellow Physician
University of California, Irvine Medical Center · Obstetrics and Gynecology
Resident Physician
Adventist Health White Memorial · Obstetrics and Gynecology
